Ferroptosis-centered Disease Response Information

General Information of the Disease (ID: DIS00055)
Name
Hemochromatosis
ICD
ICD-11: 3B10-3B11
Full List of Target(s) of This Ferroptosis-centered Disease
Unspecific Target
In total 1 item(s) under this target
Experiment 1 Reporting the Ferroptosis-centered Disease Response by This Target [1]
Responsed Disease Hemochromatosis [ICD-11: 3B10-3B11]
Responsed Drug Auranofin Investigative
 Drug Info 
Responsed Regulator Thioredoxin reductase 2, mitochondrial (TXNRD2) Suppressor
 Regulator Info 
Pathway Response JAK-STAT signaling pathway hsa04630
NF-kappa B signaling pathway hsa04064
Fatty acid metabolism hsa01212
Ferroptosis hsa04216
Cell Process Cell ferroptosis
In Vitro Model Huh-7 cells Hepatocellular carcinoma Homo sapiens CVCL_0336
HEK-293T cells Normal Homo sapiens CVCL_0063
In Vivo Model
C57BL/6J mice (7-8 weeks of age, both males and females) were purchased from Vital River Laboratory Animal Technology Co., Ltd., Beijing, China. Hfe-/-mice were kindly provided by Dr. Nancy C. Andrews. All mice were housed in a specific pathogen-free facility and fed an egg white-based AIN-76A diet containing 50 mg/kg iron (Research Diets, Inc., New Brunswick, NJ).

    Click to Show/Hide
Response regulation High-dose auranofin (AUR) induces ferroptosis and causes lipid peroxidation through inhibition of thioredoxin reductase (TXNRD) activity.In conclusion, TXNRD is a key regulator of ferroptosis, and AUR is a novel activator of hepcidin and ferroptosis via distinct mechanisms, suggesting a promising approach for treating hemochromatosis and hepcidin-deficiency related disorders.
References
Ref 1 Auranofin mitigates systemic iron overload and induces ferroptosis via distinct mechanisms. Signal Transduct Target Ther. 2020 Jul 31;5(1):138. doi: 10.1038/s41392-020-00253-0.